TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34889140

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) measurement
Number of subjects: 228

Group type: COMPARATOR
Intervention: Psychological stress measures (caregiver burden and caregiver reactions)
Number of subjects: 228
Study: 32249609

Group type: EXPERIMENTAL
Intervention: Unilateral isometric handgrip training (4×2 min at 25% of maximal voluntary contraction, 3 days/week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unilateral isometric handgrip training
Number of subjects: 20
Study: 33845867

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fostamatinib (FOS)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 171
Study: 32065415

Group type: EXPERIMENTAL
Intervention: Oral controlled-release ketamine tablets (60, 120, or 240 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Injected ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34731198

Group type: EXPERIMENTAL
Intervention: Triage by a nurse using a new extension to the Manchester Triage System during intervention weekends.
Number of subjects: 8538

Group type: COMPARATOR
Intervention: Control group where all patients remained at the ED during control weekends.
Number of subjects: 8538

Group type: EXPERIMENTAL
Intervention: Intervention group assignment to GPC.
Number of subjects: 8538

Group type: EXPERIMENTAL
Intervention: Performance of the study tool during intervention weekends.
Number of subjects: 8538
Study: 33086137

Group type: EXPERIMENTAL
Intervention: Resin coating on Zirconomer (ZR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin coating on Equia Forte (EQ)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin coating on Riva (RV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated Zirconomer (ZR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated Equia Forte (EQ)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated Riva (RV)
Number of subjects: 60
Study: 32682556

Group type: EXPERIMENTAL
Intervention: Norepinephrine 6 μg ml−1
Number of subjects: 668

Group type: COMPARATOR
Intervention: Phenylephrine 100 μg ml−1
Number of subjects: 668
Study: 35143325

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 845
Study: 33164784

Group type: EXPERIMENTAL
Intervention: Garcinia cambogia extract (GCE)/(−) – hydroxycitric acid (HCA) 1500/750 mg under fasted condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: Garcinia cambogia extract (GCE)/(−) – hydroxycitric acid (HCA) 1500/750 mg under fed condition after a high calorie breakfast (600 calories)
Number of subjects: 20
Study: 32833285

Group type: EXPERIMENTAL
Intervention: AST-guided therapy (bismuth-containing quadruple therapy guided by antimicrobial susceptibility testing)
Number of subjects: 356

Group type: COMPARATOR
Intervention: PMH-guided therapy (personal medication history-guided therapy)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: AST clarithromycin regimen
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Levofloxacin regimen
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Furazolidone-containing regimen
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Both AST and PMH therapies
Number of subjects: 356
Study: 36100890

Group type: EXPERIMENTAL
Intervention: Routine screening and management of depression in the intervention group.
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (no routine screening and management of depression).
Number of subjects: 370
Study: 34058023

Group type: EXPERIMENTAL
Intervention: Plasma transfusion (10–15 cc/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 57
Study: 33046136

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 35960344

Group type: EXPERIMENTAL
Intervention: Cannulated screws
Number of subjects: 28

Group type: COMPARATOR
Intervention: K-wires
Number of subjects: 28
Study: 32933625

Group type: EXPERIMENTAL
Intervention: Inhalation of recombinant human interferon α1b in addition to intravenous drip of acyclovir (observation group)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Intravenous drip of acyclovir (control group)
Number of subjects: 182
Study: 34635191

Group type: EXPERIMENTAL
Intervention: Dissonance‐based body project treatment (BPT)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 138
Study: 34364099

Group type: EXPERIMENTAL
Intervention: Deep SAPB
Number of subjects: 64

Group type: COMPARATOR
Intervention: Superficial SAPB
Number of subjects: 64
Study: 33258654

Group type: EXPERIMENTAL
Intervention: Local random measurements on the state, followed by postprocessing using the classical shadows framework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Existing experimental data from Brydges et al. (2019)
Number of subjects: 0
Study: 33463583

Group type: EXPERIMENTAL
Intervention: 3D‐DAVS
Number of subjects: 68

Group type: COMPARATOR
Intervention: CAM
Number of subjects: 68
Study: 32510158

Group type: EXPERIMENTAL
Intervention: Resistant starch type 3 (RS‐WM; 22 or 26 g/d for females and males, respectively)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No resistant starch (C‐WM)
Number of subjects: 19
Study: 36344002

Group type: EXPERIMENTAL
Intervention: tele-exercise rehabilitation for 6 months
Number of subjects: 794

Group type: COMPARATOR
Intervention: routine remote rehabilitation (control group)
Number of subjects: 794
Study: 33742207

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU monthly)
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5108
Study: 32236818

Group type: EXPERIMENTAL
Intervention: Nigella sativa 500 mg once daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 34873652

Group type: EXPERIMENTAL
Intervention: PoLaRS training system
Number of subjects: 38

Group type: COMPARATOR
Intervention: dVSS (Intuitive Surgical's da Vinci Skills Simulator)
Number of subjects: 38
Study: 36079744

Group type: EXPERIMENTAL
Intervention: Calcium-fortified, milk-derived protein matrix (MBPM)
Number of subjects: 0
Study: 33878556

Group type: EXPERIMENTAL
Intervention: Probiotic capsule (PC; n = 25) containing probiotic strains
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control capsule (CC; n = 20) containing a matching placebo
Number of subjects: 45
Study: 35555136

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (300 mg/70 mL) consumed acutely and for 7 days
Number of subjects: 15
Study: 32566096

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Ribavirin (RBV) with Black Cumin (BLC) and Ascorbate (ASC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sofosbuvir (SOF) and Ribavirin (RBV)
Number of subjects: 30
Study: 35599917

Group type: EXPERIMENTAL
Intervention: 30 mg.kg‐1 carnosine and anserine ingestion 60 minutes before performance (Study A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30 mg.kg‐1 carnosine and anserine (Study B)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 30 mg.kg‐1 carnosine and anserine, placebo, or antihistamines (Study C)
Number of subjects: 26
Study: 33232340

Group type: EXPERIMENTAL
Intervention: Presence of anatomical side markers (ASMs) on radiographs
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with radiographers
Number of subjects: 421
Study: 34923180

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus TACE
Number of subjects: 92

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 92
Study: 34597179

Group type: EXPERIMENTAL
Intervention: Cops & Rubbers game
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 70
Study: 35637842

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate combined with Entresto
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 120
Study: 34052580

Group type: EXPERIMENTAL
Intervention: 9‐week, interactive, family‐based intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 52
Study: 34128429

Group type: COMPARATOR
Intervention: Reference case (male, lung cancer, stage I, no symptoms)
Number of subjects: 255494
Study: 32478660

Group type: EXPERIMENTAL
Intervention: mHealth app prescription intervention
Number of subjects: 36
Study: 32319168

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Linagliptin 5 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Evogliptin/evogliptin group
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 207
Study: 36414647

Group type: EXPERIMENTAL
Intervention: Ivy leaves dry extract EA 575
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 34690120

Group type: EXPERIMENTAL
Intervention: Combined tDCS (1.5 mA, 20 min, 12 sessions) + Mindfulness-based substance abuse treatment (MBSAT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mindfulness-based substance abuse treatment (MBSAT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active tDCS (1.5 mA, 20 min, 12 sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 80
Study: 35634610

Group type: EXPERIMENTAL
Intervention: Group-A: Capsule Amoxicillin 1 gm; Tablet Clarithromycin 500 mg; Capsule Omeprazole 20 mg, twice daily for two weeks.
Number of subjects: 179

Group type: COMPARATOR
Intervention: Group-B: Capsule Amoxicillin 1 gm; Tablet Vonoprazan 20 mg, twice daily for two weeks.
Number of subjects: 179
Study: 33048829

Group type: EXPERIMENTAL
Intervention: Mobile Diabetic Foot Personal Care System (m-DAKBAS) app used for 6 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (verbal-only instruction)
Number of subjects: 88
Study: 35971757

Group type: EXPERIMENTAL
Intervention: Descriptive risk label ('very low risk')
Number of subjects: 8998

Group type: EXPERIMENTAL
Intervention: Comparison to motor-vehicle mortality
Number of subjects: 8998

Group type: EXPERIMENTAL
Intervention: Combination of both framing strategies
Number of subjects: 8998
Study: 33517953

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Bag-Valve-Mask (BVM)
Number of subjects: 92
Study: 32874103

Group type: EXPERIMENTAL
Intervention: HIITrun
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HIITbike
Number of subjects: 14
Study: 35908558

Group type: EXPERIMENTAL
Intervention: sintilimab plus IBI305 plus pemetrexed and cisplatin
Number of subjects: 444

Group type: COMPARATOR
Intervention: chemotherapy alone (pemetrexed and cisplatin)
Number of subjects: 444
Study: 33765688

Group type: EXPERIMENTAL
Intervention: Traumeel S
Number of subjects: 17

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 17
Study: 36458455

Group type: EXPERIMENTAL
Intervention: Dual transcranial direct current stimulation (tDCS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 66
Study: 33011737

Group type: EXPERIMENTAL
Intervention: n-3 FA esterified in monoacylglycerides (MAG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: n-3 FA esterified in ethyl ester (EE)
Number of subjects: 20
Study: 34033804

Group type: EXPERIMENTAL
Intervention: IV iron 1,000 mg
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 33070057

Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement intervention (8 weeks)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Neutral cue exposure
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patient's own prescribed opioid exposure
Number of subjects: 107

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 107
Study: 35510389

Group type: EXPERIMENTAL
Intervention: Flying intervention team care
Number of subjects: 157

Group type: COMPARATOR
Intervention: Patient interhospital transfer
Number of subjects: 157
Study: 32441458

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 8
Study: 33992228

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (35 Hz) twice a week for 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham Group training
Number of subjects: 12
Study: 32112920

Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 33617953

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: No targeted therapy (Control)
Number of subjects: 154
Study: 35410496

Group type: EXPERIMENTAL
Intervention: AKL-T03
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 37
Study: 32593117

Group type: EXPERIMENTAL
Intervention: Time-lapse imaging (TLI) technologies
Number of subjects: 25
Study: 34324016

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided injection
Number of subjects: 150

Group type: COMPARATOR
Intervention: Palpation-guided injection
Number of subjects: 150
Study: 33000490

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib in combination with epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (P + EC-TH)
Number of subjects: 20
Study: 33290317

Group type: EXPERIMENTAL
Intervention: Ocular discomfort scores (mean 4.28 on an 11-point scale)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index scores
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Measures of interference with activities of daily living
Number of subjects: 535
Study: 32241670

Group type: EXPERIMENTAL
Intervention: High-fidelity (HF) simulation model
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-fidelity (LF) simulation model
Number of subjects: 107
Study: 35723150

Group type: EXPERIMENTAL
Intervention: Telephone-based follow-up on top of a home-based joint protection education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based joint protection education alone
Number of subjects: 0
Study: 33735590

Group type: EXPERIMENTAL
Intervention: 60 μg HB vaccine
Number of subjects: 428
Study: 35959685

Group type: EXPERIMENTAL
Intervention: App-assisted home blood pressure monitoring (HBPM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Automated office blood pressure (OBP)
Number of subjects: 113

Group type: COMPARATOR
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Unattended 30-minute blood pressure monitoring
Number of subjects: 113
Study: 34120835

Group type: EXPERIMENTAL
Intervention: Inulin (10 g/d for females; 15 g/d for males)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Maltodextrin (6 g/d for females; 9 g/d for males)
Number of subjects: 12
Study: 35367176

Group type: EXPERIMENTAL
Intervention: OCT guidance
Number of subjects: 246

Group type: COMPARATOR
Intervention: Angiographic guidance
Number of subjects: 246
Study: 34172301

Group type: EXPERIMENTAL
Intervention: Modified Sgarbossa Criteria (MSC)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Original Sgarbossa Criteria
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Modified Sgarbossa Criteria (MSC) with concordant ST-depression in V4 to V6
Number of subjects: 251
Study: 32682668

Group type: EXPERIMENTAL
Intervention: Sufentanil (5 mcg bolus 1 minute before larger dose)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Normal saline (equal volume 1 minute before larger dose)
Number of subjects: 220
Study: 34903568

Group type: EXPERIMENTAL
Intervention: Nudge-based letter intervention
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Clinical letter intervention
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Control group (informed only of the screening results)
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Nudge-based letter intervention and Clinical letter intervention
Number of subjects: 4011
Study: 34376264

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Extraversion
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Neuroticism and Extraversion
Number of subjects: 109
Study: 33285397

Group type: EXPERIMENTAL
Intervention: Informative titles
Number of subjects: 12

Group type: COMPARATOR
Intervention: Generic titles
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simple graphs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Complex graphs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Positive results
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Negative results
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mixed results
Number of subjects: 12
Study: 32402773

Group type: EXPERIMENTAL
Intervention: Cold vapor application (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ice cube absorption (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ice cube absorption along with cold vapor application (group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All application groups (group 1, 2, 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hoarseness incidence
Number of subjects: 120
Study: 34864756

Group type: EXPERIMENTAL
Intervention: Levetiracetam plus quetiapine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo plus quetiapine
Number of subjects: 44
Study: 32561466

Group type: EXPERIMENTAL
Intervention: DM I‐TEAM (home-based multidisciplinary behavioral intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual Medical Care (UMC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: DM I‐TEAM
Number of subjects: 200
Study: 36265504

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 34911609

Group type: EXPERIMENTAL
Intervention: Family rehabilitation treatment performed by parents under the guidance of professionals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional group (online training on basic knowledge and rehabilitation training of ASD)
Number of subjects: 60
Study: 33971995

Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Isoenergetic nut-free diet (NFD)
Number of subjects: 124
Study: 34425788

Group type: EXPERIMENTAL
Intervention: 10% inclined treadmill gait
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 16% inclined treadmill gait
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inclined treadmill walking (0%, 10%, 16%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inclined treadmill walking
Number of subjects: 24
Study: 35466071

Group type: EXPERIMENTAL
Intervention: RIRS
Number of subjects: 138

Group type: COMPARATOR
Intervention: SWL
Number of subjects: 138
Study: 33844484

Group type: EXPERIMENTAL
Intervention: 30 Hz iTBS of the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: iTBS of the vertex (control)
Number of subjects: 91
Study: 34559118

Group type: EXPERIMENTAL
Intervention: EZJDR (Erzhu Jiedu Recipe) administered twice a day after meals for 48 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo granules similar to EZJDR
Number of subjects: 72
Study: 34915187

Group type: EXPERIMENTAL
Intervention: Ganglionated plexuses ablation (GPA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 102
Study: 35194433

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg sublingual twice daily, then 9 mg single dose 30 min before apheresis session and then 3 mg twice daily from +1 until engraftment)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo plus Filgrastim
Number of subjects: 51
Study: 36171519

Group type: EXPERIMENTAL
Intervention: 23.4% NaCl intravenous push
Number of subjects: 32
Study: 33507958

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid pulse therapy (HDCPT) using at least 1.5mg/kg/24h of methylprednisolone or dexamethasone equivalent
Number of subjects: 318
Study: 32780797

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT), n=16
Number of subjects: 30

Group type: COMPARATOR
Intervention: Concussion education counseling, n=14
Number of subjects: 30
Study: 35142586

Group type: EXPERIMENTAL
Intervention: Online Vaccine Education Program (VEP) videos
Number of subjects: 0

Group type: COMPARATOR
Intervention: Science-based video unrelated to vaccines
Number of subjects: 0
Study: 33099032

Group type: EXPERIMENTAL
Intervention: Teriparatide (human parathyroid hormone 1–34) for 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35953535

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation (NHFO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure ventilation (NCPAP)
Number of subjects: 0
Study: 33829482

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 13518

Group type: COMPARATOR
Intervention: Postmarketing surveillance data
Number of subjects: 13518
Study: 33279809

Group type: EXPERIMENTAL
Intervention: Semantic intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phonological intervention
Number of subjects: 20
Study: 36344585

Group type: EXPERIMENTAL
Intervention: Educational intervention based on family-centered empowerment model (four 2-hour sessions and consulting support via social network and messaging service)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 200
Study: 32278973

Group type: EXPERIMENTAL
Intervention: Medicaid enrollees with orbital fractures
Number of subjects: 1541

Group type: COMPARATOR
Intervention: Non-Medicaid enrollees
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Medicaid enrollees
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Both groups (Medicaid and non-Medicaid)
Number of subjects: 1541